Helia Medical and Siogen Biotech announced today that they have finalized an agreement for the development of a new oral insulin delivery system for type 1 diabetes. The arrangement, which is effective as of July 20, 2010, provides for the development of a Siosome® nanoparticle containing synthetic human insulin designed to be administered orally and then time-released into the bloodstream over a 12-hour period. Financial terms and specific details have not been disclosed.
Under the agreement, Helia Medical and Siogen Biotech shall work together to develop this drug for canine type 1 diabetes. The project shall commence in the third quarter of 2010. The partnership on this project will lead the veterinary and medical world to a new personalized method to manage diabetes in a more controlled and patient-friendly manner.
Siogen Biotech is Malaysia based company that focuses on developing nanoparticle delivery systems for many different drugs, compounds and substances. Siogen is a world leader in the production of silane-based nanoparticles. Siogen's main office is located in Kuala Lumpur, Malaysia and has other facilities in Germany and the UK. www.siogen.com
Helia Medical is a Wisconsin based company with operations in Raleigh, North Carolina. Helia Medical's mission is developing novel and effective drugs, devices and nanoparticles for the veterinary medical world. Helia Medical uses many cutting-edge human medical developments and applies them to veterinary medical applications. www.heliamedical.com
Helia Medical and Siogen Biotech look forward to working together on this project as well as others in the future. Many of the developments from this partnership should directly advance not only veterinary medicine, but also human medicine worldwide.
SOURCE Helia Medical www.heliamedical.com Copyright (C) 2010View Thread